BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36367853)

  • 1. Assessment of factors related to individuals who were never treated during mass drug administration for lymphatic filariasis in Ambon City, Indonesia.
    Titaley CR; Worrell CM; Ariawan I; Taihuttu YMJ; de Lima F; Naz SF; Que BJ; Krentel A
    PLoS Negl Trop Dis; 2022 Nov; 16(11):e0010900. PubMed ID: 36367853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for lymphatic filariasis and mass drug administration non-participation in Mandalay Region, Myanmar.
    Dickson BFR; Graves PM; Aye NN; Nwe TW; Wai T; Win SS; Shwe M; Douglass J; Wood P; Wangdi K; McBride WJ
    Parasit Vectors; 2021 Jan; 14(1):72. PubMed ID: 33482891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving Coverage and Compliance in Mass Drug Administration for the Elimination of LF in Two 'Endgame' Districts in Indonesia Using Micronarrative Surveys.
    Krentel A; Damayanti R; Titaley CR; Suharno N; Bradley M; Lynam T
    PLoS Negl Trop Dis; 2016 Nov; 10(11):e0005027. PubMed ID: 27812107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing knowledge about lymphatic filariasis and the implementation of mass drug administration amongst drug deliverers in three districts/cities of Indonesia.
    Titaley CR; Damayanti R; Soeharno N; Mu'asyaroh A; Bradley M; Lynam T; Krentel A
    Parasit Vectors; 2018 May; 11(1):315. PubMed ID: 29801511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-compliance to Mass Drug Administration Associated with the Low Perception of the Community Members About their Susceptibility to Lymphatic Filariasis in Ankobra, Ghana.
    Dicko I; Coulibaly YI; Sangaré M; Sarfo B; Nortey PA
    Infect Disord Drug Targets; 2020; 20(2):167-174. PubMed ID: 30727921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphatic filariasis transmission in Rufiji District, southeastern Tanzania: infection status of the human population and mosquito vectors after twelve rounds of mass drug administration.
    Jones C; Ngasala B; Derua YA; Tarimo D; Reimer L; Bockarie M; Malecela MN
    Parasit Vectors; 2018 Nov; 11(1):588. PubMed ID: 30424781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia.
    Krentel A; Wellings K
    Parasit Vectors; 2018 Mar; 11(1):179. PubMed ID: 29530082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How Thailand eliminated lymphatic filariasis as a public health problem.
    Rojanapanus S; Toothong T; Boondej P; Thammapalo S; Khuanyoung N; Santabutr W; Prempree P; Gopinath D; Ramaiah KD
    Infect Dis Poverty; 2019 May; 8(1):38. PubMed ID: 31130143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of MDA registers for Lymphatic Filariasis: Findings, and potential uses in addressing the endgame elimination challenges.
    de Souza DK; Gass K; Otchere J; Htet YM; Asiedu O; Marfo B; Biritwum NK; Boakye DA; Ahorlu CS
    PLoS Negl Trop Dis; 2020 May; 14(5):e0008306. PubMed ID: 32407319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphatic filariasis elimination status: Wuchereria bancrofti infections in human populations and factors contributing to continued transmission after seven rounds of mass drug administration in Masasi District, Tanzania.
    Lupenza ET; Gasarasi DB; Minzi OM
    PLoS One; 2022; 17(1):e0262693. PubMed ID: 35045109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment.
    Ahorlu CSK; Koka E; Adu-Amankwah S; Otchere J; de Souza DK
    BMC Public Health; 2018 Feb; 18(1):238. PubMed ID: 29433461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya.
    Njomo DW; Amuyunzu-Nyamongo M; Magambo JK; Njenga SM
    PLoS One; 2012; 7(11):e48395. PubMed ID: 23185256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Awareness and coverage of mass drug administration for elimination of lymphatic filariasis: a community based cross sectional study in Nepal.
    Adhikari RK; Sherchand JB; Mishra SR; Ranabhat K; Wagle RR
    J Community Health; 2015 Feb; 40(1):34-40. PubMed ID: 24996654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphatic filariasis in Peninsular Malaysia: a cross-sectional survey of the knowledge, attitudes, and practices of residents.
    Al-Abd NM; Nor ZM; Ahmed A; Al-Adhroey AH; Mansor M; Kassim M
    Parasit Vectors; 2014 Nov; 7():545. PubMed ID: 25428558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modelling lymphatic filariasis elimination in American Samoa: GEOFIL predicts need for new targets and six rounds of mass drug administration.
    McLure A; Graves PM; Lau C; Shaw C; Glass K
    Epidemics; 2022 Sep; 40():100591. PubMed ID: 35816826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using knowledge, attitudes and practice (KAP) surveys on lymphatic filariasis to prepare a health promotion campaign for mass drug administration in Alor District, Indonesia.
    Krentel A; Fischer P; Manoempil P; Supali T; Servais G; Rückert P
    Trop Med Int Health; 2006 Nov; 11(11):1731-40. PubMed ID: 17054754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya.
    Kusi C; Steinmann P; Merten S
    Infect Dis Poverty; 2020 Mar; 9(1):22. PubMed ID: 32114985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards elimination of lymphatic filariasis in southeastern Madagascar: Successes and challenges for interrupting transmission.
    Garchitorena A; Raza-Fanomezanjanahary EM; Mioramalala SA; Chesnais CB; Ratsimbasoa CA; Ramarosata H; Bonds MH; Rabenantoandro H
    PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006780. PubMed ID: 30222758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling the cost of engage & treat and test & treat strategies towards the elimination of lymphatic filariasis in Ghana.
    Adams NNK; Ahorlu CS; de Souza DK; Aikins M
    PLoS Negl Trop Dis; 2024 May; 18(5):e0012213. PubMed ID: 38787898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addressing barriers of community participation and access to mass drug administration for lymphatic filariasis elimination in Coastal Kenya using a participatory approach.
    Njomo DW; Kibe LW; Kimani BW; Okoyo C; Omondi WP; Sultani HM
    PLoS Negl Trop Dis; 2020 Sep; 14(9):e0008499. PubMed ID: 32936792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.